【作者】 刘辉；

【导师】 张杰英； 张祥宏；

【作者基本信息】 河北医科大学 ， 病理学与病理生理学， 2006， 硕士

【摘要】 目的:膀胱移行细胞癌( bladder transitional cell carcinoma, BTCC)为泌尿系统最常见的恶性肿瘤,生长缓慢但易于复发。膀胱移行上皮乳头状瘤和分化较好的乳头状癌约有50%术后复发,而分化差的移行细胞癌复发率可高达80%～90%。移行细胞癌的预后与肿瘤的组织学分级有较密切的关系。移行上皮乳头状瘤和移行细胞癌I级虽易复发,但患者的10年生存率可高达90%,而移行细胞癌III级患者的10年生存率仅为40%。临床上尚无可靠的方法做到早期预测。近年来,随着分子生物学及免疫学技术的飞速发展,BTCC的肿瘤标志物也不断增加,如:BTCC相关抗原(McAb):M344和19A211,癌基因包括c-erbB-2、c-ras、c-myc、c-jun和mdm2等。但上述所有的肿瘤标志物的敏感度和特异度均不高,因此对新的膀胱肿瘤标志物的探寻研究,从而获得膀胱癌的早期诊断、监测疗效及评估预后的新手段,一直是医务工作者关注的焦点。VHL(von Hippel-Lindau)基因是一种肿瘤抑制基因,是1993年Latif等对克隆的3号染色体短臂3p25-26区域cDNA进行分析发现的,并通过位置克隆的方法分离成功。最初该基因是在VHL综合征中被认识的,VHL综合征是一种常染色体显性遗传病,与VHL基因的丢失或失活有密切关系。随着基因研究的深入,发现在膀胱移行细胞癌组织中,更多还原

【Abstract】 Objective: Bladder transitional cell carcinoma (BTCC) is the most common malignant tumor in urinary system. About 50% papilloma and well-differentiated papillary carcinoma recur after operation, while recurrence rate was as high as 80%~90% in poorly differentiated BTCC. The prognosis of BTCC was closely related to differentiation of tumor. Although easy to recur, 10-year survival rate could reach 90% for the patients with bladder papilloma and grade I BTCC, while that for the patients with poorly differentiated BTCC (grade III) was only 40%. There are still no reliable early predictors for recurrence and invasion of BTCC in clinical practice. In the past few decades, as the rapid development of immunological and molecular biological technologies, different tumor marks, such as BTCC tumor associated antigens (McAb) M344 and 19A211; oncogene: c-erbB-2, c-ras, c-myc, c-jun, mdm2, etc, for BTCC were evaluated for their significance in diagnosis, prediction of invasion and recurrence as well as prognosis, yet the sensitivity and specificity was not satisfactory enough. Thus, people have been diligently seeking for other early predicators for early diagnosis and assessing prognosis.VHL (von Hippel-Lindau) gene is tumor suppressor gene更多还原